The aim of this study is to evaluate the effect of clodronate on apoptosis of human systemic lupus erythematosus circulating mononuclear cells and to analyze possible correlations with changes in autoantibody production in vitro. Lympho-monocytes from 20 SLE patients were isolated and incubated with or without addition of 1 μM clodronate for 72 hours. Apoptosis and release of genomic material was assessed by immunofluorescent detection of cleaved caspase-3 and by Cell-Death-Detection ELISAPLUS kit (Roche). Anti-Nucleosome IgG and anti-dsDNA IgM and IgG autoantibody levels were determined in supernatants by commercially available ELISA kits. Clodronate induced apoptosis in monocytes as confirmed by cleaved caspase-3 immunostaining and by quantification of cleaved nucleosome in the supernatants (treated 0.22±0.05 O.D. vs untreated 0.09±0.04 O.D.; P<0.001). This finding was coupled with a significant increasing in supernatants of IgG anti-Nucleosome (treated 6.5±1.1 vs untreated 5.5±0.6 IU/mL; p=0.001) and IgM (treated 3.0±1.3 vs 2.2±0.9 IU/mL; p=0.02) and IgG (treated 4.0±1.8 vs untreated 2.8±1.5 IU/mL; p=0.02) anti-dsDNA autoantibody levels. Our findings stressed the proapoptotic activity of clodronate, as well as its potential autoimmunity induction in SLE mononuclear circulating cells. Clinical studies could clarify the role of bisphosphonates on autoantibody production and worsening of disease activity.
JankoCSchornCGrossmayerGEFreyBHerrmannMGaiplUSMunozLE. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev2008; 8:9–12.
2.
CacciapagliaFSpadaccioCChelloMGiganteACocciaRAfeltraAAmorosoA. Apoptotic molecular mechanisms implicated in autoimmune diseases. Eur Rev Med Pharmacol Sci2009; 13:23–40.
3.
MunozLEGaiplUSFranzS. SLE—a disease of clearance deficiency?Rheumatology (Oxford)2005; 44:1101–7.
4.
HerrmannMWinklerTGaiplULorenzHGeilerTKaldenJR. Etiopathogenesis of systemic lupus erythematosus. Int Arch Allergy Immunol2000; 123:28–35.
5.
ShoenfeldYSzyper-KravitzMWitteT. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann NY Acad Sci2007; 1108:227–39.
6.
SchulzeCMunozLEFranzSSarterKChaurioRAGaiplUSHerrmannM. Clearance deficiency—a potential link between infections and autoimmunity. Autoimmun Rev2008; 8:5–8.
7.
SzabóITarnawskiAS. Apoptosis in the gastric mucosa: molecular mechanisms, basic and clinical implications. J Physiol Pharmacol2000; 51:3–15.
8.
RogersMJFrithJCLuckmanSPCoxonFPBenfordHLMönkkönenJAuriolaSChiltonKMRussellRG. Molecular mechanisms of action of bisphosphonates. Bone1999; 24(S):73–79.
9.
FrithJCMonkkonenJBlackburnGMRussellRGRogersMJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 59-(beta, gammadichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1997; 12:1358–67.
10.
SelanderKSMonkkonenJKarhukorpiEKHarkonenPHannuniemiRVaananenHK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol1996; 50:1127–38.
11.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40:1725.
12.
Rucker-MartinCPeckerFGodreauDHatemSN. Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro. Cardiovascular Research2002; 55:38–52.
13.
YlitaloPHolliKMonkkonenJEloHAJuhakoskiALiukko-SipiSYlitaloR. Comparison of pharmacokinetics of clodronate after single and repeated doses. Int J Clin Pharmacol Ther1999; 37:294–300.
14.
DrakeMTClarkeBLKhoslaS. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc2008; 83:1032–45.
15.
SenDKeenRW. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus2001; 10:227–32.
16.
YeapSSFauziARKongNCHalimAGSoehardyZRahimahIChowSKGohEM. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol2008; 35:2344–47.
17.
EbetinoFHBaylessAVAmburgeyJIbbotsonKJDansereauSEbrahimpourA. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon Relat Elem1996; 109/110:217–20.
18.
OstermanTKippoKLaurenLPasanenIHannuniemiRSellmanR. A comparison of clodronate and indomethacin in the treatment of adjuvant arthritis. Inflamm Res1997; 46:79–85.
19.
BarreraPBlomAvan LentPL. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum2000; 43:1951–59.
20.
SelanderKSMonkkonenJKarhukorpiEKHarkonenPHannuniemiRVaananenHK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol1996; 50:1127–38.
21.
DennyMFChandaroyPKillenPDCaricchioRLewisEERichardsonBCLeeKDGavalchinJKaplanMJ. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol2006; 176:2095–104.
22.
GaiplUSKuhnASheriffAMunozLEFranzSVollREKaldenJRHerrmannM. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun2006; 9:173–87.
23.
RichardsonBCYungRLJohnsonKJRowsePELalwaniND. Monocyte apoptosis in patients with active lupus. Arthritis Rheum1996; 39:1432–4.
24.
HsiehSCYuHSLinWWSunKHTsaiCYHuangDFTsaiYYYuCL. Anti-SSB/La is one of the antineutrophil autoantibodies responsible for neutropenia and functional impairment of polymorphonuclear neutrophils in patients with systemic lupus erythematosus. Clin Exp Immunol2003; 131:506–16.
25.
CohenPLCaricchioRAbrahamVCamenischTDJennetteJCRoubeyRAEarpHSMatsushimaGReapEA. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med2002; 196:135–40.
26.
HanayamaRTanakaMMiyasakaKAozasaKKoikeMUchiyamaYNagataS. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science2004; 304:1147–50.
27.
FadokVABrattonDLKonowalAFreedPWWestcottJYHensonPM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest1998; 101:890–98.
28.
HuynhMLFadokVAHensonPM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J Clin Invest2002; 109:41–50.
29.
KurosakaKWatanabeNKobayashiY. Production of proinflammatory cytokines by phorbol myristate acetate-treated THP-1 cells and monocyte-derived macrophages after phagocytosis of apoptotic CTLL-2 cells. J Immunol1998; 161:6245–9.
30.
RoverePSabbadiniMGFazziniFBondanzaAZimmermannVSRugarliCManfrediAA. Remnants of suicidal cells fostering systemic autoaggression: apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum2000; 43:1663–72.
31.
MiwaKAsanoMHoraiRIwakuraYNagataSSudaT. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med1998; 4:1287–92.
